Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13163463 | 0.86 | HSD11B1 (0.40) | MGAT2WDR5OPRM1HSD11B1 | |
| SCHEMBL21820652 | 0.83 | WDR5 (0.38) | MGAT2WDR5OPRM1HSD11B1NPSR1 | |
| SCHEMBL2288499 | 0.81 | PDE4A (0.45) | WDR5OPRM1HSD11B1MEN1NPC1 | |
| SCHEMBL19212372 | 0.81 | ALDH1A1 (0.39) | MGAT2OPRM1HSD11B1NPC1ALDH1A1 | |
| SCHEMBL990207 | 0.81 | OPRM1 (0.51) | MGAT2OPRM1KMT2A | |
| SCHEMBL24775285 | 0.81 | OPRM1 (0.34) | MGAT2WDR5OPRM1 | |
| SCHEMBL8097373 | 0.80 | OPRM1 (0.45) | OPRM1MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL2300 | 0.79 | OPRM1 (0.46) | WDR5OPRM1MEN1NPC1ALDH1A1 | |
| SCHEMBL571854 | 0.79 | MGAT2 (0.38) | MGAT2WDR5HSD11B1MEN1ALDH1A1 | |
| SCHEMBL21874287 | 0.77 | ALDH1A1 (0.49) | MGAT2NPSR1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2609092-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | CXCR3, CXCR1, CCR2 | MGAT2 3025/4885WDR5 3071/4885OPRM1 1169/4885 |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | MGAT2 2951/4885WDR5 2214/4885OPRM1 1988/4885 |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | MGAT2 1739/4885WDR5 3532/4885OPRM1 6/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | MGAT2 3257/4885WDR5 4022/4885OPRM1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.